MedTrace Logo

Coronavirus Response - Active Support for Hospitalised Covid-19 Patients

NCT04343001 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2020-11-19

No results posted yet for this study

Summary

The CRASH-19 trial is a multinational, open-label, factorial, randomised trial in adults hospitalised with suspected or confirmed acute COVID-19 infection.

Conditions

Interventions

DRUG

Aspirin

Aspirin 150mg

DRUG

Losartan

Losartan 100mg

DRUG

Simvastatin

Simvastatin 80mg

Sponsors & Collaborators

  • London School of Hygiene and Tropical Medicine

    lead OTHER

Principal Investigators

  • Haleema Shakur-Still · London School of Hygiene and Tropical Medicine

  • Ian Roberts · London School of Hygiene and Tropical Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2021-04-30
Completion
2021-08-31

Countries

  • Nigeria
  • Pakistan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04343001 on ClinicalTrials.gov